Previous Close | 4.6300 |
Open | 4.6500 |
Bid | 5.0200 x 1400 |
Ask | 5.0000 x 1100 |
Day's Range | 4.6500 - 5.1800 |
52 Week Range | 3.6600 - 11.8200 |
Volume | |
Avg. Volume | 342,551 |
Market Cap | 168.919M |
Beta (5Y Monthly) | -1.14 |
PE Ratio (TTM) | 3.79 |
EPS (TTM) | 1.3120 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for CODX
Investors took the measure of healthcare testing products specialist Co-Diagnostics (NASDAQ: CODX) and gave it an enthusiastic thumbs-up on Thursday: The company's stock closed the session more than 7% higher. The stock's upward move was propelled by fresh news from the company about its potential role in combating the latest potential global health threat. Thursday morning, Co-Diagnostics announced that it has leveraged its molecular diagnostics platform to finish the principal design work on a PCR test for monkeypox, a rare and occasionally deadly virus first detected in Southern Africa.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 2022 Global Investment Conference, being held in-person and virtually on May 23-26 in Miami, Florida.